Bellerophon Therapeutics, Inc.
BLPH
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.91% | 8.72% | 4.80% | -15.74% | -28.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.70% | -7.74% | 4.79% | 13.34% | 2.57% |
| Operating Income | 48.85% | 34.26% | 23.49% | -13.34% | -2.57% |
| Income Before Tax | 51.03% | 35.08% | 23.68% | -13.77% | 7.66% |
| Income Tax Expenses | 47.17% | 47.17% | -105.22% | -34.28% | -34.28% |
| Earnings from Continuing Operations | 51.52% | 33.51% | 36.62% | -11.69% | 11.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.52% | 33.51% | 36.62% | -11.69% | 11.18% |
| EBIT | 48.85% | 34.26% | 23.49% | -13.34% | -2.57% |
| EBITDA | 48.68% | 34.12% | 23.35% | -13.59% | -2.71% |
| EPS Basic | 58.58% | 38.56% | 35.63% | -11.10% | 11.51% |
| Normalized Basic EPS | 57.26% | 40.03% | 23.37% | -15.63% | -5.59% |
| EPS Diluted | 58.04% | 38.24% | 35.43% | -10.74% | 11.95% |
| Normalized Diluted EPS | 57.10% | 39.88% | 23.20% | -15.63% | -5.59% |
| Average Basic Shares Outstanding | 16.38% | 9.44% | 2.50% | 0.51% | 0.36% |
| Average Diluted Shares Outstanding | 17.02% | 10.09% | 3.15% | 0.51% | 0.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
